Identification of Clinical and Genomic Features Associated with SARS-CoV-2 Reinfections.

Publication date: Jun 11, 2025

Although SARS-CoV-2 reinfections remain a concern for healthcare systems worldwide, the factors driving them are still not fully understood. In this study, we examined data for 3303 individuals who experienced two SARS-CoV-2 infections between March 2020 and May 2022 from both clinical and viral genomics perspectives. Our findings indicate that viral evolution was the primary driver of reinfection. However, chronic conditions were common among reinfected individuals, including those under 26 years old, suggesting that the presence of underlying and/or chronic conditions increases susceptibility to reinfection. The median time elapsed between infections was one year, often coinciding with the emergence of new variants. While vaccination showed only a limited protective effect against reinfection, it drastically decreased the hospitalization rate, underscoring its role in mitigating disease severity. Our findings point to the need for more flexible vaccination strategies, especially for individuals with chronic conditions. Understanding the interactions between host factors and viral evolution is critical to strengthening prevention strategies and reducing the burden of reinfections and their possible long-term complications.

Open Access PDF

Concepts Keywords
Driving Adolescent
Genomic Adult
Hospitalization Aged
Old comorbidities
Viruses COVID-19
COVID-19
Evolution, Molecular
Female
Genome, Viral
Genomics
Hospitalization
Humans
Male
Middle Aged
Reinfection
reinfection
SARS-CoV-2
SARS-CoV-2
vaccination
viral evolution
Young Adult

Semantics

Type Source Name
disease MESH Reinfections
disease MESH SARS-CoV-2 infections
disease MESH chronic conditions
disease IDO susceptibility
disease MESH infections
disease IDO role
disease IDO host
disease MESH complications
disease MESH Respiratory Diseases
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease IDO infection
disease MESH long COVID
disease IDO history
disease IDO primary infection
disease IDO nucleic acid
disease IDO assay
disease MESH privacy
disease MESH morbidity
disease MESH breakthrough infection
disease MESH neoplasia
disease IDO process
drug DRUGBANK Spinosad

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *